Trial · NCT04692467
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Systolic Blood Pressure (SBP) | Baseline, 12 months | For participants receiving Standard of Care, 120 of the 126 (95.2%) had a 12-month visit. For the participants receiving the intervention, 122 of the 124 (98.4%) had a 12-month visit. | mmHg | MEAN |
| SECONDARY | Change in Number of Participants With HIV Viral Suppression as Measured by HIV-1 RNA Viral Loads < 1,000 Copies/mL | Baseline, 12 months | At the 12-month visit, 8 participants in the Standard of Care arm and 5 participants in the intervention arm were missing viral load data. | participants | NUMBER |
| SECONDARY | Change in HIV Medication Adherence as Measured by Number of Participants With > 90% Adherence Using 4-day Pill Recalls | Baseline, 6 months and 12 months | participants | NUMBER | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 1 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 2 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 3 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adverse Events | Followup month 5 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 6 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 8 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 9 | 1 participant in the standard of care arm was excluded from analysis because the participant died of causes unrelated to the research prior to follow-up month 9. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Who Have Adverse Events Related to Amlodipine, Including Dizziness, Fainting, Lower Extremity Edema, and Any Other Symptoms Which May be Related. | Followup month 12 | 2 participants in the standard of care arm were excluded from analysis because these participants died of causes unrelated to the research prior to follow-up month 12. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Are Enrolled at Baseline and Remain in the Study by 12 Months | Baseline, 12 months | 2 participants in the standard of care arm were excluded from analysis because these participants died of causes unrelated to the research prior to follow-up month 12. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Acceptability of Study Intervention Assessed by Qualitative Interviews Among Participants and Providers | 12 months | Focus-group discussions were conducted with participants who received the intervention. A subset of 16 participants were randomly selected and called to conduct FGD. Individual interviews were conducted with providers. All physicians (two) who were involved in the study were interviewed. One nurse was excluded as they could not be contacted as they had left the clinic. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04692467/outcomes